Claims for Patent: 8,796,245

Summary for Patent: 8,796,245

Title:	C7-fluoro substituted tetracycline compounds
Abstract:	The present invention is directed to a compound represented by Structural Formula (A): ##STR00001## or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
Inventor(s):	Zhou; Jingye (Shanghai, CN), Xiao; Xiao-Yi (Lexington, MA), Plamondon; Louis (Montreal, CA), Hunt; Diana Katharine (Cambridge, MA), Clark; Roger B. (Lexington, MA), Zahler; Robert B. (Pennington, NJ)
Assignee:	TetraPhase Pharmaceuticals, Inc. (Watertown, MA)
Application Number:	13/718,909
Patent Claims:	1. A method of reducing infections caused by bacteria in a subject in need thereof, comprising administering to said subject an effective amount of a compound represented by the following structural formula: ##STR00222## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the infection is caused by a Gram-positive bacteria. 3. The method of claim 2, wherein the bacteria is selected from Staphylococcus spp., Streptococcus spp., Propionibacterium spp., Enterococcus spp., Bacillus spp., Corynebacterium spp., Nocardia spp., Clostridium spp., Actinobacteria spp., and Listeria spp. 4. The method of claim 3, wherein the bacteria is Bacillus anthracis. 5. The method of claim 1, wherein the infection is caused by a Gram-negative bacteria. 6. The method of claim 5, wherein the bacteria is selected from selected from Enterobactericeae, Bacteroidaceae, Pasteurellae, Pseudornonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, any species of Proteeae, Acinetobacter spp., Helicobacter spp., Campylobacter spp., and Vibrionaceae. 7. The method of claim 6, wherein the bacteria is E. coli or Klebsiella pneumonia. 8. The method of claim 5, wherein the bacteria is Yersinia pestis or Francisella tularensis. 9. The method of claim 1, wherein the infection is caused by K pneumoniae, Salmonella, E. hirae, A. baumanii, M catarrhalis, H influenzae, P. aeruginosa, E. faecium, E. coli, S. aureus or E. faecalis. 10. The method of claim 1, wherein the infection is caused by chlamydiae, Legionella spp., Mycoplasma spp. or rickettsiae. 11. The method of claim 1, wherein the infection is a skin infection, a respiratory tract infection or a hospital acquired infection. 12. The method of claim 1, wherein the infection is an intra-abdominal infection. 13. The method of claim 1, wherein the infection is a urinary tract infection. 14. The method of claim 1, wherein the infection is gonorrhea. 15. The method of claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is administered alone. 16. The method of claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is administered in combination with one or more additional therapeutic agents.